Valuation: AbbVie

Market Cap 442B 386B 356B 329B 624B 42,111B 635B 4,256B 1,671B 20,745B 1,658B 1,622B 71,318B P/E 2026 *
30.2x
P/E 2027 * 23.5x
Enterprise Value 497B 434B 401B 370B 702B 47,357B 714B 4,787B 1,880B 23,330B 1,864B 1,824B 80,203B EV / Sales 2026 *
7.39x
EV / Sales 2027 * 6.71x
Free-Float
95.71%
Yield 2026 *
2.74%
Yield 2027 * 2.89%
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 68 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 442B
-2.24%-0.70%+50.72%+162.98% 1,085B
-0.91%-1.01%+62.79%+60.93% 624B
+0.33%-1.17%+27.98%+26.90% 332B
-3.89%-11.22%+20.78%+26.07% 277B
-0.02%-2.85%+25.27%+44.88% 282B
+0.66%-1.42%-29.26%-39.30% 217B
+0.03%-0.70%+21.15%+61.92% 196B
-3.69%+0.38%+13.59%+71.89% 167B
-0.10%+2.26%-5.92%-32.02% 138B
Average -1.81%-1.42%+20.79%+42.69% 368.73B
Weighted average by Cap. -2.13%-0.60%+34.85%+76.82%

Financials

2026 *2027 *
Net sales 67.23B 58.8B 54.24B 50.09B 95.05B 6,412B 96.65B 648B 254B 3,159B 252B 247B 10,859B 72.73B 63.62B 58.68B 54.19B 103B 6,936B 105B 701B 275B 3,417B 273B 267B 11,747B
Net income 14.35B 12.55B 11.58B 10.7B 20.29B 1,369B 20.64B 138B 54.33B 674B 53.89B 52.72B 2,318B 19.02B 16.64B 15.35B 14.18B 26.9B 1,814B 27.35B 183B 72.01B 894B 71.43B 69.87B 3,073B
Net Debt 55B 48.11B 44.38B 40.99B 77.77B 5,246B 79.08B 530B 208B 2,584B 207B 202B 8,884B 46.43B 40.61B 37.46B 34.6B 65.64B 4,428B 66.75B 448B 176B 2,181B 174B 171B 7,499B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
AA